Poulton Jeffrey V.

Poulton Jeffrey V., EVP and Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), has demonstrated a consistent pattern of selling activity based on SEC Form 4 filings. Over 66 reported transactions, all have been sales, totaling approximately $5.93 million in aggregate value, with no recorded purchases. The most recent cluster of sales occurred on March 4, 2026, with seven transactions ranging from $34,881 to $264,901, collectively amounting to over $756,000. Just two days prior, on March 2, 2026, Poulton executed ten additional sales, including larger dispositions of $176,804 and $148,762, alongside smaller transactions between $17,630 and $77,152. Earlier in February 2026, a single sale of $695,201 stood out as the largest individual transaction in the dataset. The transactions suggest a sustained divestment strategy, with all activity concentrated in ALNY stock. While some sales appear to be routine, such as the January 2026 dispositions totaling $22,973, the frequency and scale of the March 2026 sales—particularly the multi-day clustering—indicate an accelerated reduction in holdings. The absence of any buys reinforces a one-directional trend. Given Poulton’s executive role, the sales likely represent planned dispositions rather than discretionary trades, but the filings provide no indication of whether these transactions were prearranged under Rule 10b5-1 plans. The data reflects a clear and exclusive focus on liquidating ALNY positions over time.